Bristol-Myers Squibb Co (BMY):企業の財務・戦略的SWOT分析

◆英語タイトル:Bristol-Myers Squibb Co (BMY) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15769
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:80
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,625見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,875見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Bristol-Myers Squibb Co (BMY) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company discovers, develops, licenses, manufactures, markets, distributes and sells medicines to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects. The company offers its products across the world to retail pharmacies, wholesalers, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, Japan and other countries. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Bristol-Myers Squibb Co Key Recent Developments

Mar 28,2019 Bristol-Myers Squibb and Concerto HealthAI Announce Strategic Agreement to Broaden Uses of Real-World Evidence and Accelerate Precision Oncology Innovations
Mar 20,2019 Parker Institute to share pancreatic cancer trial results, microbiome and immunotherapy research, and new CAR-T approaches at AACR 2019
Mar 19,2019 Bristol-Myers Squibb files investor presentation highlighting significant benefits of pending transaction with Celgene
Mar 01,2019 BMS faces shareholder opposition to $74bn Celgene acquisition

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Bristol-Myers Squibb Co – Key Facts
Bristol-Myers Squibb Co – Key Employees
Bristol-Myers Squibb Co – Key Employee Biographies
Bristol-Myers Squibb Co – Major Products and Services
Bristol-Myers Squibb Co – History
Bristol-Myers Squibb Co – Company Statement
Bristol-Myers Squibb Co – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Bristol-Myers Squibb Co – Business Description
Business Segment: BioPharmaceuticals
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Others
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States
Performance
R&D Overview
Bristol-Myers Squibb Co – Corporate Strategy
Bristol-Myers Squibb Co – SWOT Analysis
SWOT Analysis – Overview
Bristol-Myers Squibb Co – Strengths
Bristol-Myers Squibb Co – Weaknesses
Bristol-Myers Squibb Co – Opportunities
Bristol-Myers Squibb Co – Threats
Bristol-Myers Squibb Co – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Bristol-Myers Squibb Co, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 28, 2019: Bristol-Myers Squibb and Concerto HealthAI Announce Strategic Agreement to Broaden Uses of Real-World Evidence and Accelerate Precision Oncology Innovations
Mar 20, 2019: Parker Institute to share pancreatic cancer trial results, microbiome and immunotherapy research, and new CAR-T approaches at AACR 2019
Mar 19, 2019: Bristol-Myers Squibb files investor presentation highlighting significant benefits of pending transaction with Celgene
Mar 01, 2019: BMS faces shareholder opposition to $74bn Celgene acquisition
Feb 28, 2019: Bristol-Myers Squibb issues statement in response to Starboard’s letter
Feb 27, 2019: Top pharma executives testify before US Senate over high prices
Feb 05, 2019: US Senate invites seven pharma majors to testify on price hikes
Jan 24, 2019: Bristol-Myers Squibb Reports 2018 Fourth Quarter and Full Year Financial Results
Jan 24, 2019: EORTC collaborates with IDDI on ground-breaking statistical method for individualisation of therapy
Jan 15, 2019: Inovio’s dMAb PD-1 Checkpoint Inhibitors Demonstrate Higher and More Prolonged Expression Compared to Native Pembrolizumab and Nivolumab Sequences In Preclinical Studies
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Bristol-Myers Squibb Co, Key Facts
Bristol-Myers Squibb Co, Key Employees
Bristol-Myers Squibb Co, Key Employee Biographies
Bristol-Myers Squibb Co, Major Products and Services
Bristol-Myers Squibb Co, History
Bristol-Myers Squibb Co, Subsidiaries
Bristol-Myers Squibb Co, Joint Venture
Bristol-Myers Squibb Co, Key Competitors
Bristol-Myers Squibb Co, Ratios based on current share price
Bristol-Myers Squibb Co, Annual Ratios
Bristol-Myers Squibb Co, Annual Ratios (Cont...1)
Bristol-Myers Squibb Co, Annual Ratios (Cont...2)
Bristol-Myers Squibb Co, Interim Ratios
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Bristol-Myers Squibb Co, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Bristol-Myers Squibb Co, Performance Chart (2014 - 2018)
Bristol-Myers Squibb Co, Ratio Charts
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Bristol-Myers Squibb Co (BMY):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Omnicell Inc (OMCL):医療機器:M&Aディール及び事業提携情報
    Summary Omnicell Inc (Omnicell) is a provider of automation and business analytics software solutions. It provides medication control and patient safety solutions to enhance operational efficiency and patient care in acute healthcare facilities. The company offers automation solutions such as medica …
  • Mitsui-Soko Co., Ltd. (9302):企業財務及び戦略的SWOT分析
    Summary Mitsui-Soko Co., Ltd. (Mitsui-Soko) is a service providing company that offers warehousing and marine, land, and air freight transportation services. The company offers services such as warehouse storage service, distribution processing, functional facilities, air import and export forwardin …
  • Dongfang Electric Corporation Limited (1072):企業のM&A・提携動向(発電分野)
    Summary Dongfang Electric Corporation Limited (DECL), a subsidiary of Dongfang Electric Corporation, is a manufacturer of power equipment and supplier of spare parts for power projects. The product line of the company includes thermal power units, hydro power units, nuclear power units, wind power u …
  • Hydrogen Future Corporation (formerly A5 Laboratories, Inc.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Hydrogen Future Corporation (fo …
  • Beckman Coulter, Inc.:企業の戦略・SWOT・財務情報
    Beckman Coulter, Inc. - Strategy, SWOT and Corporate Finance Report Summary Beckman Coulter, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Energisa SA (ENGI3):企業のM&A・提携動向(エネルギー分野)
    Summary Energisa SA (Energisa) is a power utility that generates, distributes and sells electricity. The company generates electricity using wind, small hydropower, and biomass resources. Energisa also operates and maintains hydroelectric power plants for other companies; constructs and refurbishes …
  • EndoChoice Inc. (GI):企業のM&A・提携動向(医療機器分野)
    Summary EndoChoice Inc. (EndoChoice) is a medical device company that manufactures and commercializes new technologies platforms for the healthcare sector. The company offers medical devices, diagnostic equipments, infection control products and endoscopic imaging systems. Its medical device product …
  • Fibria Celulose S.A. (formerly Votorantim Celulose e Papel S.A.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Fibria Celulose S.A. (formerly …
  • Cascades, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Cascades, Inc. Mergers and Acqu …
  • Hwasung Industrial Co., Ltd. (002460):企業財務及び戦略的SWOT分析
    Summary Hwasung Industrial Co., Ltd. (Hwasung Industrial) is a construction company that offers engineering services. The company offers civil engineering, architecture, housing, landscaping, environment and renewable energy; steel fabrication, PC business and engineering services. It provides civil …
  • The Stars Group Inc (TSGI):企業の財務・戦略的SWOT分析
    The Stars Group Inc (TSGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Numab Innovation AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Numab Innovation AG (Numab) is a developer of novel therapeutics for the treatment of severe diseases. The company’s pipeline products include ND007, ND009, ND016, ND017, ND023, ND026, and ND021. Its ND007 is a bispecific antibody fragment which is being evaluated for the treatment of autoim …
  • Dil Ltd (506414):企業財務及び戦略的SWOT分析
    Summary Dil Ltd (Dil) formerly Duphar-Interfran Ltd. is a diversified pharmaceutical company that provides healthcare related products and services. The company offers products in the areas such as biotechnology, environmental solutions, pharmaceuticals, and vitamins. It also provides services such …
  • Advanced Cancer Therapeutics(製薬・医療分野):企業M&A動向
    Summary Advanced Cancer Therapeutics (ACT) is a biotechnology company. The company discovers and develops novel cancer therapeutics. Its products include ACT-GRO-777, PU27, PFKFB3, choline kinase and human papillomavirus vaccine. ACT provides ACT-GRO-777 which is an aptamer that binds to a protein c …
  • Sany Heavy Industry Co. Ltd.の企業概要及び財務/SWOT分析
    Sany Heavy Industry Co. Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and qu …
  • HCP, Inc.:企業概要およびSWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "HCP, Inc." The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. World Market Intelligence strictl …
  • Dyas BV:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Dyas BV Mergers and Acquisition …
  • SKY Network Television Limited (SKT):企業の財務・戦略的SWOT分析
    SKY Network Television Limited (SKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • B. Braun Melsungen AG:企業の戦略的SWOT分析
    B. Braun Melsungen AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Alpha Packaging LLC:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Alpha Packaging LLC Mergers and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆